■ The Korea Disease Control and Prevention Agency announced on the 17th that GC Biopharma, EuBiologics, and Korea Biomedical's corporations will participate in the mRNA vaccine development support project, which gained attention during the COVID-19 pandemic. mRNA transmits genetic information copied from DNA to ribosomes, where proteins are produced. The vaccine injects mRNA into the body to induce an immune response. The Korea Disease Control and Prevention Agency plans to quickly develop and supply vaccines for the next pandemic using mRNA. To this end, it will invest 505.2 billion won by 2028. The four corporations will participate as clinical research and development institutions for the vaccine. GC Biopharma noted that its goal this year is to secure results from animal non-clinical experiments and obtain approval for phase 1 clinical trial plans.
■ Curocell announced on the 17th that it has administered the immune cell therapy Anvaxel to patients with systemic lupus erythematosus (SLE). Systemic lupus erythematosus is a disease that causes problems in the immune system. It causes inflammation and damage to the skin, joints, kidneys, lungs, heart, and central nervous system and is said to be difficult to cure. Curocell administered Anvaxel to a patient in their 40s at the Seoul St. Mary's Hospital of The Catholic University of Korea last month. The Ministry of Food and Drug Safety is currently processing the product approval procedure for Anvaxel.
■ HANALL BIOPHARMA announced on the 17th that it has won the '2025 National Industry Grand Award' in the research and development sector for two consecutive years. The National Industry Grand Award is given to corporations that advance industries through technological innovation. The award is hosted by the Korea Institute for Industrial Policy Studies and co-sponsored by the Ministry of Trade, Industry and Energy and the Small and Medium Enterprises and Startups Agency. The company was recognized for its contributions to the bio industry by developing new drugs.
■ Humedix, Huons, and Huons Biopharma announced on the 17th that they recently participated in the dermatology exhibition 'Dubai Derma 2025' held in the United Arab Emirates. Humedix has signed supply contracts for the hyaluronic acid filler 'Elavie' with Saudi Arabia, Lebanon, and Syria. Dubai Derma is an event where medical device, aesthetic companies, and professionals gather.
■ CAREGEN announced on the 17th that it introduced the 'Dr. CYJ Hair Filler,' which helps prevent hair loss, at 'Dubai Derma 2025.' The company describes the product as improving scalp blood flow and inducing hair follicle regeneration to promote hair growth. It is injected directly into the scalp. Patients can return to their daily lives immediately after the procedure without a separate recovery period.
■ Y-Biologics announced on the 17th that it plans to participate in the American Association for Cancer Research (AACR) to be held in Chicago, USA. The company plans to present research results on next-generation antibody-drug conjugates (ADCs). The research is based on pH-sensitive antibody technology that selects antibodies activated in acidic conditions. The American Association for Cancer Research will be held from the 25th to the 30th (local time).
■ JCs Medical announced on the 17th that it participated in the 'IMCAS Americas 2025' World Aesthetic Plastic Surgery Congress held in São Paulo, Brazil. The event is the largest aesthetic medicine and treatment event in Latin America. The company introduced high-frequency aesthetic medical devices 'Densiti' and ultrasound medical devices 'Linear G.'
■ Healthcare corporations Imocog and Hurei Positive announced on the 17th that they have signed a business agreement to advance digital senior care. They will jointly develop a life-cycle smart healthcare solution and share research technologies and resources. They plan to establish an integrated model for digital treatment, prevention, and management targeting the elderly.
■ Boramae Traditional Korean Medicine Hospital announced on the 17th that it has signed business agreements with Seoul Barun Hospital and Oulim Hospital to establish a 'Korean and Western Medicine Collaborative Treatment System.' Patients undergoing spine and joint surgery at partner hospitals can be hospitalized at Boramae Traditional Korean Medicine Hospital for rehabilitation treatment. It will facilitate referrals for patients visiting Boramae Traditional Korean Medicine Hospital to have surgery at partner hospitals.